Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL versus BINOSTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL versus BINOSTO.
ACTONEL vs BINOSTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone matrix and inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
70 mg orally once weekly
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Terminal elimination half-life is approximately 10 hours; clinical context: supports once-weekly dosing for osteoporosis
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Renal: 50% excreted unchanged in urine; fecal: 20% as unabsorbed drug; biliary: negligible
Category C
Category C
Bisphosphonate
Bisphosphonate